Description

🧬 Overview

ARA-290 is a non-erythropoietic peptide derived from erythropoietin (EPO). Unlike traditional EPO, it does not stimulate red blood cell production, but instead targets tissue-protective pathways. This makes it a key compound in research focused on inflammation, nerve regeneration, and cellular protection without hematopoietic effects.

⚙️ Technical Profile

• Peptide Name: ARA-290 (Cibinetide)
• Type: EPO-derived peptide (non-erythropoietic)
• Sequence Length: 11 amino acids
• Molecular Weight: ~1257 g/mol
• Structure: Linear peptide
• Target: Innate repair receptor (IRR)
• Biological Role: Tissue protection and anti-inflammatory action
• Purity (Research Grade): Typically ≥98%
• Form: Lyophilized powder
• Solubility: Water-soluble

⚡ Mechanism of Action

ARA-290 works by selectively activating the innate repair receptor (IRR), a pathway involved in tissue protection and healing. This activation helps reduce inflammatory responses and supports cellular recovery in damaged tissues.

It is particularly studied for its effects on nerve cells, where it may help reduce neuropathic inflammation and support regeneration. Additionally, it influences cytokine signaling, helping to control excessive immune responses.

Through these mechanisms, ARA-290 contributes to improved tissue resilience and reduced inflammation.

🔬 Research Context

ARA-290 has been extensively studied in research related to neuropathy, chronic inflammation, and tissue injury. It is commonly explored in models involving nerve damage, metabolic disorders, and inflammatory conditions.

Research highlights its potential in reducing pain signaling and supporting nerve repair without affecting red blood cell production. Its targeted mechanism makes it a promising candidate in regenerative and neuroprotective studies.

Ongoing studies continue to evaluate its broader applications in inflammation control, nerve health, and tissue recovery.